Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 47Melanoma 7Lung Neoplasms 7Small Cell Lung Carcinoma 6Carcinoma, Renal Cell 6Head and Neck Neoplasms 5Triple Negative Breast Neoplasms 4Advanced NSCLC 4Squamous Cell Carcinoma of Head and Neck 3Neoplasms 3Parkinson Disease 4, Autosomal Dominant Lewy Body 2Neoplasm Metastasis 2NSCLC 2Colorectal Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma, Hepatocellular 2Breast Neoplasms 2Urinary Bladder Neoplasms 1Small Cell Lung Cancer Extensive Stage 1Skin Neoplasms 1Sarcopenia 1SCLC 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Non-small Cell Lung Cancer Metastatic 1NSCLC Stage IV Without EGFR/ALK Mutation 1Mesothelioma, Malignant 1Kidney Neoplasms 1Influenza, Human 1Hyperthermia 1

Interventions

Pemetrexed 1Immune Checkpoint Inhibitors 1Drug Therapy 1Carboplatin 1CP protocol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
First-line Advanced NSCLC Patients × Immune Checkpoint Inhibitors × Thoracic × Clear all
NCT07171606 2025-12-18

A Phase II Study of SSGJ-706 Monotherapy and Combination Therapy in Advanced Non-Small Cell Lung Cancer(NSCLC) Patients

Shenyang Sunshine Pharmaceutical Co., LTD.

Phase 2 Recruiting
240 enrolled
Thoracic

First-line Advanced NSCLC Patients

Data powered by HemOnc (CC BY 4.0) Colophon âš¡